All In Biotech

Investigational drug · Phase 3

Amlenetug

Also called: Lu AF82422

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple System Atrophy.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

1

Any phase or sponsor naming "Amlenetug"

First trial start

2021

Nov 16, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Amlenetug", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Multiple System Atrophy

Largest trials

Live from ClinicalTrials.gov: studies naming "Amlenetug" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 8 on PubMed

Also in development for Multiple System Atrophy

  • PBT434ATH434Phase 23 trials

    Alterity Therapeutics · Multiple System Atrophy

  • Foralumab NasalPhase 22 trials

    Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS

  • TEV-56286EmrusolminPhase 22 trials

    Teva · Multiple System Atrophy

  • exidavnemabPhase 21 trial

    BioArctic AB · Parkinson Disease, Multiple System Atrophy

  • TAK-341MEDI1341Phase 21 trial

    Takeda · Multiple System Atrophy

  • YA-101Phase 21 trial

    Dasher Neuroscience Inc. · Multiple System Atrophy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.